

Awakn Life Sciences Corp. (formerly 1169082 BC LTD.)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE COMPANY'S FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE YEARS ENDED MAY 31, 2021 AND 2020

DATE AND SUBJECT OF REPORT

The following Management Discussion & Analysis ("MD&A") is prepared as at September 14, 2021 and is intended to assist in the understanding of the trends and significant changes in the financial condition and results of operations of 1169082 BC Ltd. (hereinafter "082BC" or the "Company") for the years ended May 31, 2021 and 2020. The MD&A should be read in conjunction with the audited consolidated financial statements for the years ended May 31, 2021 and 2020 as filed on SEDAR.

SCOPE OF ANALYSIS

The following is a discussion and analysis of Awakn Life Sciences Corp. (formerly 1169082 B.C. Ltd.). The Company's audited consolidated financial statements for the years ended May 31, 2021 and 2020 were prepared in accordance with the International Financial Reporting Standards ("IFRS") and any interpretations of IFRS as issued by the International Accounting Standards Board (IASB). The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments classified in accordance with measurement standards under IFRS. These consolidated financial statements have been prepared using IFRS principles applicable to a going concern, which contemplate the realization of assets and settlement of liabilities in the normal course of business as they come due.

FORWARD LOOKING STATEMENTS

The information set forth in this MD&A contains statements concerning future results, future performance, intentions, objectives, plans and expectations that are, or may be deemed to be, forward-looking statements. These statements concerning possible or assumed future results of operations of the Company are preceded by, followed by or include the words 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'forecasts,' or similar expressions. Forward-looking statements are not guarantees of future performance. These forward-looking statements are based on current expectations that involve numerous risks and uncertainties, including, but not limited to, those identified in the Risks Factors section. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. These factors should be considered carefully, and readers should not place undue reliance on forward-looking statements. The Company may not provide updates or revise any forward-looking

statements, except those otherwise required under paragraph 5.8(2) of NI 51-102, whether written or oral that may be made by or on the Company's behalf.

TRENDS

Other than as disclosed in this MD&A, the Company is not aware of any trends, uncertainties, demands, commitments or events which are reasonably likely to have a material effect upon its revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.

GENERAL BUSINESS AND DEVELOPMENT

The Company is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (drugs and therapies in combination) to treat Addiction.

The Company's registered and records office is located at Suite 600, 890 West Pender Street, Vancouver, British Columbia, V6C 1J9 and the head office is located at Suite 200, 366 Bay St., Toronto, Ontario, M5H4B2.

The Company is a reporting Company in the Provinces of Alberta, British Columbia and Ontario. All public filings for the Company on the SEDAR website www.sedar.com.

Business Chronology

The Company was incorporated as a wholly owned subsidiary of reporting Company Hemagenetics Technologies Corp. ("HTC") on June 21, 2018 under the laws of British Columbia, Canada (see Plan of Arrangement).

From incorporation to date, no significant operations have begun and management continues to assess possible business opportunities and/or acquisitions for the Company.

PLAN OF ARRANGEMENT

On June 26, 2018, the Company entered into a statutory arrangement with HemaGenetics Technologies Corp. ("HTC") under a plan of arrangement pursuant to an arrangement agreement (the "Arrangement") entered into between the Company, HTC, Agri Tech International Inc. (formerly 1169029 B.C. Ltd.), 1169071 B.C. Ltd., 1169077 B.C. Ltd., Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), and 1169082 B.C. Ltd. Under the Arrangement, the effective date for the Arrangement can be set separately as between HTC and each of the other parties to the Arrangement. The Arrangement received final B.C. supreme court approval on July 19, 2018.

On April 29, 2019, the Company completed a statutory arrangement with 1169082 B.C. Ltd. under a plan of arrangement pursuant to an arrangement agreement (the "Arrangement") entered into

between the Company, Hemagenetics Technologies Corp., Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.) , Agri Tech Farms International Inc. (formerly, 1169029 B.C. Ltd.), 1169032 B.C. Ltd., 1169071 B.C. Ltd., and 1169077 B.C. Ltd. Under the Arrangement, the effective date for the Arrangement can be set separately as between the Company and each of the other parties to the Arrangement. Pursuant to the Arrangement, the effective date for the Arrangement with 1169082 B.C. Ltd. was set for April 29, 2019.

Pursuant to the Arrangement, the Company's shareholders of record as of October 15, 2018 eligible to receive shares of 1169082 B.C. Ltd. under the Arrangement received 199,968 common shares with an aggregate value of \$1,000 in 1169082 B.C. Ltd. issued effective April 29, 2019. As a result, the Company became a reporting issuer in the provinces of B.C. and Alberta.

LETTER OF INTENT WITH GREENY

On November 15, 2019, the Company entered into a non-binding letter of intent with Greeny Collaboration Group (Canada) Inc. ("Greeny"), which sets out the terms and conditions relating to a proposed transaction pursuant to which the Company will acquire the business of Greeny. Following completion of the Transaction, the Company will continue to carry on the business of Greeny.

Pursuant to the LOI, the Company and Greeny have agreed to negotiate in good faith to enter into a binding definitive transaction agreement, which will set out the terms and conditions of the Transaction, and which shall contain customary indemnities, representations and warranties and other terms in form and substance satisfactory to both parties, and pursuant to which the parties intend to agree to complete a business combination by way of a three-cornered amalgamation under the BCBCA. Pursuant to the terms of the Amalgamation Agreement, Greeny will amalgamate with the Company Subco to form a new company to carry on the business of Greeny as a wholly-owned operating subsidiary of the Company. Upon completion of the Amalgamation, each shareholder of Greeny will be entitled to receive one (1) common share of the Company for every one (1) common share of Greeny held by such shareholder. In addition, each holder of a warrant or stock option of Greeny will receive an equal number of replacement warrants or replacement options of the Company.

The LOI has been terminated during the year ended May 31, 2020 based on mutual agreement between the parties involved.

TRANSACTION WITH AWAKN INC.

On March 3, 2021, the Company entered into a non-binding letter of intent with Awakn Life Sciences Inc. ("Awakn Inc."), whereby the Company and Awakn Inc. have agreement to negotiate exclusively in respect of a transaction to combine their respective businesses. Closing of the transaction is subject to completion of a satisfactory due diligence, the entering into of a definitive agreement and respective shareholder approvals. This letter of intent will be terminated if a definitive agreement has not been entered within 60 days after the date of this letter of intent. There can be no assurances the transaction will be completed as proposed or at all.

On May 13, 2021, the Company entered into a definitive binding amalgamation agreement (the “Amalgamation Agreement”) with Awakn Inc., which, subject to certain conditions and applicable shareholder and regulatory approvals, will result in a reverse takeover of the Company by Awakn Inc. (the “Transaction”). The resulting issuer from the Transaction (the “Resulting Issuer”) will carry on the business of Awakn Inc.

Pursuant to the terms of the Amalgamation Agreement, the Transaction will be completed by way of a three-cornered amalgamation involving 2835517 Ontario Ltd., a wholly-owned subsidiary of the Company, amalgamating with Awakn Inc. to form a single, wholly-owned subsidiary of the Resulting Issuer.

In accordance with the Amalgamation Agreement, on June 16, 2021, the Company completed its reverse takeover transaction of Awakn Inc. The Company has changed its name to “Awakn Life Sciences Corp.” and consolidated its issued and outstanding shares on the basis of one (1) post-consolidation share for every 42.5105 pre-consolidation shares (the “Consolidation”). The Company also received final approval to list its common shares on the Neo Exchange Inc. and trading commenced on June 23, 2021 under the stock symbol “AWKN”.

LIQUIDITY AND CAPITAL RESOURCES

As at May 31, 2021, the Company had working capital deficit of \$36,549.

During the year ended May 31, 2021, the Company incurred a net loss of \$19,342 and cumulative losses and deficit of \$37,549.

The continuation of the Company as a going-concern is dependent on its ability to raise additional capital or debt financing, including on reasonable terms, in order to meet business objectives towards achieving profitable business operations.

SHARE CAPITAL AND OUTSTANDING SHARE DATA

Common Shares:

Authorized — unlimited Common shares, without par value
— unlimited Preferred shares, without par value

Issued and Outstanding: 199,968 common shares as of May 31, 2021 and 28,250,092 as of September 14, 2021, subsequent to the reverse takeover transaction of Awakn Inc.

On June 16, 2020, the Company completed the Consolidation. The accompanying financial statements give retroactive effect to such share split and all share and per share amounts have been adjusted accordingly.

RESULTS OF OPERATIONS

SELECTED ANNUAL INFORMATION

| | May 31, 2021 \$ | May 31, 2020 \$ |
|------------------------------------|-----------------------|-----------------------|
| Revenue | — | — |
| Expenses | 19,342 | 11,358 |
| Net loss | (19,342) | (11,358) |
| Loss per share – basic and diluted | (0.00) | (0.00) |
| Assets | — | — |
| Long-term liabilities | — | — |
| Working capital (deficiency) | (36,549) | (17,207) |

Expenses consisted of general and administration of NIL (2020: \$132), transfer agent and filing fees of \$11,964 (2020: \$258), profession fees of \$7,378 (2020: \$9,568) and management fees of NIL (2020: 1,500). Expenses increased in current year was mainly due to increase in transfer agent and filing fees and professional fee in connection with the reverse takeover transaction of Awakn Inc.

SELECTED QUARTERLY INFORMATION

SUMMARY OF FINANCIAL RESULTS FOR EIGHT MOST RECENTLY COMPLETED QUARTERS

The following table summarizes the financial results of operations for the eight most recent fiscal quarters:

| | May 31, 2021 (Q4) \$ | February 28, 2021 (Q3) \$ | November 30, 2020 (Q2) \$ | August 31, 2020 (Q1) \$ | May 31, 2020 (Q4) \$ | February 29, 2020 (Q3) \$ | November 30, 2019 (Q2) \$ | August 31, 2019 (Q1) \$ |
|---------------------------------------|----------------------------|------------------------------------|------------------------------------|-------------------------------|----------------------------|---------------------------------|------------------------------------|-------------------------------|
| Revenue | — | — | — | — | — | — | — | — |
| Expenses | 16,845 | 1,725 | (1,195) | 1,967 | 3,658 | 1,285 | 6,415 | — |
| Net income (loss) | (16,845) | (1,725) | 1,195 | (1,967) | (3,658) | (1,285) | (6,415) | — |
| Loss per share – basic and diluted | (0.08) | (0.01) | 0.01 | (0.01) | (0.02) | (0.01) | (0.03) | (0.00) |
| Assets | — | — | — | — | — | — | — | — |
| Long-term liabilities | — | — | — | — | — | — | — | — |
| Working capital (deficiency) | (36,549) | (19,704) | (17,979) | (19,174) | (17,207) | (13,549) | (12,264) | (5,849) |

INTERIM RESULTS

For the three months ended May 31, 2021 (Q4)

For the three months ended May 31, 2021, the Company had net loss and total comprehensive loss of \$16,845 compared to a net loss and comprehensive loss of 3,658 for the comparable period. Balance increased in current period was mainly due to increase in transfer agent and filing fees and professional fees incurred for in connection with the reverse takeover transaction of Awakn Inc.

For the three months ended February 28, 2021 (Q3)

For the three months ended February 28, 2021, the Company had net loss and total comprehensive loss of \$1,500 related to professional fees compared to a net loss and comprehensive loss of \$1,285 for the comparable period from December 1, 2020 to February 28, 2021. No material change was noted.

For the three months ended to November 30, 2020 (Q2)

For the three months ended November 30, 2020, the Company had net income and total comprehensive income of \$1,195 compared to a net loss and comprehensive loss of \$6,415 from September 1, 2019 to November 30, 2019. Balance decrease in current period was mainly due to decrease in professional fee incurred and reversal of over-accrual of audit fee in current period.

For the three months ended to August 31, 2020 (Q1)

For the three months ended August 31, 2020, the Company had net loss and total comprehensive loss of \$1,967 compared to a net loss and comprehensive loss of \$Nil from June 1, 2019 to August 31, 2019.

For the three months ended May 31, 2020 (Q4)

For the three months ended May 31, 2020, the Company had net loss and total comprehensive loss of \$3,658 related to professional fees compared to a net loss and comprehensive loss of \$6,496 for the comparable period from March 1, 2019 to May 31, 2019. Balance decreased in current period was mainly due to securities and transfer agent fee included in last period for the execution of the plan of arrangement.

For the three months ended February 29, 2020 (Q3)

For the three months ended February 29, 2020, the Company had net loss and total comprehensive loss of \$1,285 related to professional fees compared to a net loss and comprehensive loss of \$Nil for the comparable period from December 1, 2018 to February 28, 2019.

For the three months ended November 30, 2019 (Q2)

For the three months ended November 30, 2019, the Company had net loss and total comprehensive loss of \$(6,415) compared to a net loss and comprehensive loss of \$Nil for the comparable period from September 1, 2018 to November 30, 2018.

A breakdown of the \$6,415 in expenses for Q2 are as follows:

- (i) Professional fees of \$4,783; and
- (ii) Management fees of \$1,500; and
- (iii) Securities and transfer agent fees of \$132.

For the three months ended to August 31, 2019 (Q1)

For the three months ended August 31, 2019, the Company had net loss and total comprehensive loss of \$Nil compared to a net loss and comprehensive loss of \$(353) related to incorporation costs for the comparable period from June 21, 2018 (inception) to August 31, 2018.

RELATED PARTY TRANSACTIONS

Due to related parties is comprised of \$5,851 (2020: \$5,851) due to a company controlled by a director of the Company. These are unsecured, non-interest bearing and due on demand.

During the year ended May 31, 2021, the following transactions occurred with a related party:

| | Year ended May 31, 2021 | Period ended May 31, 2020 |
|---|----------------------------|------------------------------|
| | \$ | \$ |
| Key management transactions: | | |
| Management fees to the director of the Company | - | 1,852 |
| Professional fees to a company related to the director of the Company | - | 3,999 |
| | <hr/> | <hr/> |

All related party transactions are in the normal course of operations and have been measured at the agreed to amounts, which is the amount of consideration established and agreed to by the related parties.

INCOME TAXES

Estimated taxable income for the year ended May 31, 2021 is \$Nil.

Deferred tax assets have not been recognized because it is not probable that future taxable income will be available against which the company can utilize the benefits from the deductible temporary differences and unused tax losses.

MANAGEMENT OF INDUSTRY AND FINANCIAL RISK

The Company is in the healthcare section in Canada and manages related industry risk issues directly. However, the Company does not currently have any active operations and as such is not exposed to any related risks.

The Company's has minimal exposure to any financial risks having not commenced commercial operations.

The Company's primary financial risk to *liquidity risk* due to its reliance on vendors and consultants continuing to extend payment terms, and management accruing expenses for unpaid services. Any one or more of these liquidity risks may have a material financial impact on the Company, should favourable loans, services, and/or terms become no longer available to the Company.

OFF-BALANCE SHEET TRANSACTIONS

The Company has not entered into any off-balance sheet arrangements or commitments.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES

Refer to the Company's audited consolidated financial statements for the years ended May 31, 2021 and 2020 for details of the significant accounting policies and estimates adopted by the Company.

RISK AND UNCERTAINTIES

Core Business

The Company is in the healthcare and related technology sector in Canada.

It will require significant risk and capital for the Company working towards establishing viable business in the payment processing sector, if ever. There can be no assurance that the Company ever becomes established or profitable in the sector, even with significant capital investment and business expertise.

While the development of healthcare services and related technology sector in Canada may result in profitable operations, marketing may also contribute to successful business. Notwithstanding, it is impossible to ensure that any healthcare and related technology sector in Canada and market strategy planned by the Company will result in profitable commercial sales and operations. Whether the company will be commercially viable depends on a number of factors, some of which are the particular attributes of the industry, as well as competitors' strategies and market factors. Some of these are cyclical and government regulations, including farming and land use regulations.

Some of these risks include, but not limited to, the following:

Significant capital investment, personnel, management, and consultants will be required for the development of any products or services in the healthcare sector. There can be no assurance that the Company will be able to achieve this with limited resources or without raising significant capital through debt and/or equity financings, if available on acceptable terms, and that will dilute shareholders.

Uninsured Risks

The Company may carry insurance to protect against certain risks in such amounts as it considers adequate. Risks not insured against include key person insurance as the Company heavily relies on the company officers and directors.

COVID-19

Since March 2020, the outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company and its operations in future periods.

Negative Operating Cash Flows

As the Company is in early development stages, it will continue to have negative operating cash flows without the development of revenue streams from its business. Positive operating cash flows require the Company to complete successful setup of active operations whether through organic business development or acquisition.

Risks Related as a Going Concern

The ability of the Company to continue as a going concern is uncertain and dependent upon its ability to achieve profitable operations, obtain additional capital and receive continued support from its shareholders. Management of the Company will have to raise capital through private placements or debt financing and proposes to continue to do so through future private placements and offerings. The outcome of these matters cannot be predicted at this time.

Reliance on Key Personnel, Service Provider, and Advisors

The Company relies heavily on its officers, its service provider, and business advisors. The loss of their services may have a material adverse effect on the business and going concern of the Company. There can be no assurance that one or all of the employees of, and contractors engaged by, the Company will continue in the employ of, or in a consulting capacity to, the Company or that they will not set up competing businesses or accept positions with competitors. There is no guarantee that certain employees of, and contractors to, the Company who have access to confidential information will not disclose the confidential information.

Operating History and Expected Losses

The Company expects to make significant investments in order to develop its services, increase marketing efforts, improve its operations, conduct research and development and update its equipment. As a result, start-up operating losses are expected, and such losses may be greater than anticipated, which could have a significant effect on the long-term viability of the Company.

Growth Management

In executing the Company's business plan for the future, there will be significant pressure on management, operations, technical, and other assets or resources. The Company anticipates that its operating costs will increase substantially in the future when and if it is able to identify a viable farming project. In order to manage its growth, the Company will have to increase the number of its technical, engineering, and operational employees and efficiently manage its employees, while at the same time efficiently maintaining a large number of relationships with third parties. There can be no assurance that the Company will be able to meet these growth objectives.

Conflicts of Interest

The directors of the Company also serve as directors and officers in other private and public companies involved in other businesses. Consequently, there exists the possibility for such directors and officers to be in a position of conflict. Any decisions made by these individuals involving the Company will be made in accordance with their duties and obligations to deal fairly and in good faith with the Company and such other companies.

MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The information provided in this report as referenced from the Company's financial statements for the referenced reporting period is the sole responsibility of management. In the preparation of the information along with related and accompanying statements and estimates contained herein, management uses careful judgement in assessing the values (or future values) of certain assets or liabilities. It is the opinion of management that such estimates are fair and accurate as presented.

OTHER INFORMATION

Additional information on the Company is available on SEDAR at www.sedar.com.